最終更新日:2022/12/24
Recently, mogamulizumab (anti-CCR4 antibody, Kyowa Hakko Kirin) and obinutuzumab (anti-CD20 antibody, Genentech/Roche) with depleted core fucoses have been approved for marketing, and several glycoengineered antibodies are in clinical studies and are being developed as next generation therapeutic monoclonal antibodies.
編集履歴(0)
元となった例文
Recently,
mogamulizumab
(anti-CCR4
antibody,
Kyowa
Hakko
Kirin)
and
obinutuzumab
(anti-CD20
antibody,
Genentech/Roche)
with
depleted
core
fucoses
have
been
approved
for
marketing,
and
several
glycoengineered
antibodies
are
in
clinical
studies
and
are
being
developed
as
next
generation
therapeutic
monoclonal
antibodies.